.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Argus Health
Boehringer Ingelheim
Moodys
Queensland Health
Daiichi Sankyo
Healthtrust
Farmers Insurance
Cipla
Julphar

Generated: July 25, 2017

DrugPatentWatch Database Preview

ATROVENT HFA Drug Profile

« Back to Dashboard

What is the patent landscape for Atrovent Hfa, and what generic Atrovent Hfa alternatives are available?

Atrovent Hfa is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are three patents protecting this drug.

This drug has fifty-four patent family members in thirty-seven countries.

The generic ingredient in ATROVENT HFA is ipratropium bromide. There are seven drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the ipratropium bromide profile page.

Summary for Tradename: ATROVENT HFA

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list26
Clinical Trials: see list202
Patent Applications: see list5,225
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ATROVENT HFA at DailyMed

Pharmacology for Tradename: ATROVENT HFA

Drug ClassAnticholinergic
Mechanism of ActionCholinergic Antagonists
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim
ATROVENT HFA
ipratropium bromide
AEROSOL, METERED;INHALATION021527-001Nov 27, 2004RXYesYes► Subscribe► SubscribeY ► Subscribe
Boehringer Ingelheim
ATROVENT HFA
ipratropium bromide
AEROSOL, METERED;INHALATION021527-001Nov 27, 2004RXYesYes► Subscribe► SubscribeY ► Subscribe
Boehringer Ingelheim
ATROVENT HFA
ipratropium bromide
AEROSOL, METERED;INHALATION021527-001Nov 27, 2004RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ATROVENT HFA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim
ATROVENT HFA
ipratropium bromide
AEROSOL, METERED;INHALATION021527-001Nov 27, 2004► Subscribe► Subscribe
Boehringer Ingelheim
ATROVENT HFA
ipratropium bromide
AEROSOL, METERED;INHALATION021527-001Nov 27, 2004► Subscribe► Subscribe
Boehringer Ingelheim
ATROVENT HFA
ipratropium bromide
AEROSOL, METERED;INHALATION021527-001Nov 27, 2004► Subscribe► Subscribe
Boehringer Ingelheim
ATROVENT HFA
ipratropium bromide
AEROSOL, METERED;INHALATION021527-001Nov 27, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ATROVENT HFA

Country Document Number Estimated Expiration
Germany50009558► Subscribe
New Zealand516317► Subscribe
Norway20015718► Subscribe
Japan5436430► Subscribe
South Africa200109597► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Express Scripts
US Army
QuintilesIMS
Farmers Insurance
Johnson and Johnson
Boehringer Ingelheim
Citi
Argus Health
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot